title: Re: Lepore et al.: Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings (Ophthalmology 2014;121:2212-9).
authors.affiliation: Consultant, Retina and Vitreous services, LV Prasad Eye Institute, Bhubaneswar, India.
authors.forename: Tapas Ranjan
authors.initials: TR
authors.lastname: Padhi
authors.affiliation: Assistant Professor, Ophthalmology and Visual Sciences, Kellogg Eye Center, University of Michigan, Ann Arbor, Michigan. Electronic address: cbesirli@med.umich.edu.
authors.forename: Cagri G
authors.initials: CG
authors.lastname: Besirli
mesh_terms: D020533:Angiogenesis Inhibitors / Q000627:therapeutic use*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D006801:Humans; D017075:Laser Coagulation; D012178:Retinopathy of Prematurity / Q000175:diagnosis* / Q000628:therapy*
chemical_list: D020533:Angiogenesis Inhibitors; D061067:Antibodies, Monoclonal, Humanized